Page 5,205«..1020..5,2045,2055,2065,207..5,2105,220..»

SPAARx and BusinessOne Technologies Announce Specialty Pharmacy Drug & Health Utilization Data-Sharing Alliance

Posted: Published on June 4th, 2013

BENSALEM, Pa.--(BUSINESS WIRE)-- The Specialty Pharmacy Association of America (SPAARx), the largest national association representing the broad interests of the specialty pharmacy industry, today announced it is has agreed to participate in an alliance with BusinessOne Technologies (BusinessOne) wherein BusinessOne will provide access to its national / regional market access data and data integration technology. The alliance will allow SPAARx and BusinessOne to develop a new standard for data management and analytics in the specialty pharmacy segment. Throughout the alliance, BusinessOne will be syndicating content and market intelligence to SPAARx which will make this data available to participating specialty pharmacies in the form of advisories and trend reports. The analytics will help ensure that SPAARx membership stays fully informed regarding payer-market access challenges, risks and opportunities. SPAARx is excited about the alliance with BusinessOne Technologies, said Bill Sullivan, Interim Executive Director of the Specialty Pharmacy Association of America. Sullivan continued, BusinessOne is in the forefront of healthcare and drug data analytics and having access to their data adds a new dimension to our understanding of access, reimbursement and distribution trends nationally. The more our membership understands managed market trends the better positioned they will be to compete in the marketplace … Continue reading →

Posted in Pharmacy | Comments Off on SPAARx and BusinessOne Technologies Announce Specialty Pharmacy Drug & Health Utilization Data-Sharing Alliance

Novel method uses clays to grow human bone

Posted: Published on June 3rd, 2013

Washington, June 3 (ANI): Indian origin researchers at North Dakota State University, Fargo, are making strides in tissue engineering - designing scaffolds that may lead to ways to regenerate bone. The research of Dr. Kalpana Katti, Dr. Dinesh Katti and graduate student Avinash Ambre includes a novel method that uses nanosized clays to make scaffolds to mineralize bone minerals such as hydroxyapatite. The NDSU research team's 3-D mesh scaffold is comprised of degradable materials that are compatible to human tissue. Over time, the cells generate bone and the scaffold deteriorates. As indicated in the NDSU team's published scientific research from 2008 to 2013, the nanoclays enhance the mechanical properties of the scaffold by enabling scaffold to bear load while bone generates. An interesting finding by the Katti group has shown that the nanoclays also impart useful biological properties to the scaffold. "The biomineralized nanoclays also impart osteogenic or bone-forming abilities to the scaffold to enable birth of bone," said Dr. Kalpana Katti, Distinguished Professor of civil engineering at NDSU. "Although it would have been exciting to say that this finding had a 'Eureka moment,' this discovery was a methodical exploration of simulations and modeling, indicating that amino acid modified nanoclays … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Novel method uses clays to grow human bone

HALO-96 PQR: How to Measure Potency of Hematopoietic

Posted: Published on June 3rd, 2013

HALO-96 PQR: How to Measure Potency of Hematopoietic Mesenchymal Stem Cell Products This last technical guide video on potency demonstrates how potency is measured using using the HALO-96 PQR assay kit using umbilical cord blood stem cells a... By: HemoGenix … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on HALO-96 PQR: How to Measure Potency of Hematopoietic

Arteriocyte announces Launch of Compass Biomedical

Posted: Published on June 3rd, 2013

CLEVELAND, June 3, 2013 /PRNewswire/ --Arteriocyte, Inc., a leading biotechnology company that is focused on developing and enabling commercial stem cell based therapies announced the launch of Compass Biomedical, the commercial tools division of Arteriocyte that supplies novel cell culturing products and technologies for translational research. As part of the Arteriocyte family, Compass Biomedical has access to the pipeline of cutting edge research from Arteriocyte's research and development team, as well as collaboration partnerships with leading research institutions making Compass Biomedical an ideal choice to help accelerate the transition from basic research to clinical application. Compass Biomedical already supplies 3 product lines: 1) NANEX Cell Culture and Expansion Kit; 2) Adhere-34 Cell Culture and Expansion Bag; and 3) PLUS Cell Culture Supplement. Compass Biomedical's core products are based upon the NANEX biofunctional nanofiber-based technology, that was designed to partially mimic key features of human bone marrow enabling rapid ex vivo cell growth and expansion while maintaining the stem cell's properties. It is an ideal solution for rapidly culturing hematopoietic stem and progenitor cells (HSC/HPCs) for basic research, therapeutics, drug discovery, and screening. These expanded cells have been used to grow new blood cells (including red blood cells and platelets) and … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Arteriocyte announces Launch of Compass Biomedical

Grant Established by Bioness and Stroke Survivor Will Provide Bioness L300® Foot Drop Systems to Stroke Patients in Need

Posted: Published on June 3rd, 2013

VALENCIA, Calif.--(BUSINESS WIRE)-- National Stroke Association, stroke survivor Erik Cherdak and Bioness today announced the formation of the Cherdak-Bioness Grant, a philanthropic fund which will provide the Bioness L300 to 30 individuals through the National Stroke Associations Stroke Center Network of rehabilitation facilities. Bioness L300 Foot Drop System is designed to help individuals who suffer from foot drop, a condition which causes difficulty walking due to an impaired ability to lift the foot, and is commonly a result of stroke. Each year nearly 800,000 people suffer strokes and it is a leading cause of serious, long-term disability in the United States. Many survivors are left with paralysis and balance problems that can significantly affect their mobility, said Jim Baranski, CEO of National Stroke Association. Our mission at National Stroke Association is to reduce the incidence and impact of stroke, and giving survivors an opportunity to regain some independence through this grant is a huge step forward in this mission. Funding for Cherdak-Bioness Grant is made possible by Erik Cherdak, who was motivated to take action following his personal experience with stroke, and after learning of the success the Bioness technology has offered in improving the quality of life for other … Continue reading →

Comments Off on Grant Established by Bioness and Stroke Survivor Will Provide Bioness L300® Foot Drop Systems to Stroke Patients in Need

5 weeks after 'mini-stroke,' Algeria's leader in limbo

Posted: Published on June 3rd, 2013

Algerian President Abdelaziz Bouteflika in 2009. UPI/John Angelillo License photo ALGIERS, Algeria, June 3 (UPI) -- Five weeks ago, on April 27, Algerian President Abdelaziz Bouteflika suffered what the government called a "mini-stroke and was whisked off to France for treatment. Government officials say he's recovering, but many people now suspect something's going on. The Algerian and French media are saying the 76-year-old president's health is deteriorating and there are rumors he's dead. These concerns have deepened in recent days after Algerian authorities closed down two Algerian dailies that quoted French medical sources as saying Bouteflika was in a coma in the Val de Grace Hospital in Paris where he was flown after his reported stroke. Prime Minister Abdelmalek Sellal sought to quell the rumors and broke the official silence on Bouteflika May 20, saying the president was "never in danger," and was convalescing well in Paris. "I would like to reassure our compatriots on the state of health of the president of the republic," Sellal announced. "His health is improving day by day." But Algerians remain perplexed and suspicious of the leadership in advance of presidential elections scheduled for April 2014. Abderrazzak Mukri, leader of the main Islamist party, … Continue reading →

Comments Off on 5 weeks after 'mini-stroke,' Algeria's leader in limbo

StemCells, Inc.'s Spinal Cord Injury Trial Approved by Health Canada

Posted: Published on June 3rd, 2013

NEWARK, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that Health Canada has authorized the Company to expand its Phase I/II clinical trial for chronic spinal cord injury into Canada. The Phase I/II trial, currently underway in Zurich, Switzerland, is designed to evaluate the safety and preliminary efficacy of the Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) as a treatment for chronic spinal cord injury. With this authorization from Health Canada, the Company is actively working to open one or more trial sites in Canada and begin screening patients. "This should be very welcome news for spinal cord injury patients in North America," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "One of the patients in our trial is a Canadian and he endured some challenging logistics to get to and from Switzerland. The addition of sites located in North America will significantly ease the burden on Canada- and US-based patients and their families who may wish to participate in our trial. "In addition, given the excellent safety profile and encouraging results seen to date in the three patients with complete injury, we have … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on StemCells, Inc.'s Spinal Cord Injury Trial Approved by Health Canada

3 Keys to Acadia's Future

Posted: Published on June 3rd, 2013

By Brandy Betz - June 3, 2013 | Tickers: ACAD, AGN | 0 Comments Brandy is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited. Acadia Pharmaceuticals (NASDAQ: ACAD) had a busy couple of months. The new member of the Nasdaq Biotechnology Index recently completed a $150 million public offering to help push lead drug candidate pimavanserin, a treatment for Parkinsons disease psychosis, or PDP. In April, Acadia shares soared over 50% when the company filed an accelerated new drug application for pimavanserin after talks with the Food and Drug Administration. The pipelines scant but includes areas of unmet need and an Allergan (NYSE: AGN) partnership. Whats next for Acadia? Here are three things to know about Acadias future. 1. Lead Drug Pimavanserins accelerated filing pertains to PDP, but the companys pursuing mid-stage trials for additional indications that include Alzheimers disease psychosis, or ADP. Parkinsons disease has no cure but the symptom treatments work by increasing the brains supply of dopamine. Pimavanserin is non-dopaminergic -- meaning, it doesnt impact dopamine levels and thus wont interfere with primary treatment. Acadia estimates that PDP occurs in up to 60% … Continue reading →

Posted in Parkinson's Treatment | Comments Off on 3 Keys to Acadia's Future

NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinson's Disease

Posted: Published on June 3rd, 2013

NESS ZIONA, Israel, June 3, 2013 /PRNewswire/ -- NeuroDerm, Ltd. was informed today that it was awarded, for the second time, a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support the clinical development of its subcutaneously delivered drug for the treatment of Parkinson's disease. These funds, part of the Foundation's 2013 Therapeutic Pipeline program, will support an upcoming phase 2 clinical trial with ND0612, a novel drug for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula under development for continuous administration through a sub-cutaneous delivery patch that would maintain constant levodopa plasma concentrations. ND0612 has so far been shown in human trials to be safe and tolerable and, for the first time in man, to maintain steady state, clinically meaningful levodopa plasma concentrations. ND0612 can be administered subcutaneously in a convenient manner and has the potential to significantly improve the current standard of treatment of Parkinson's disease patients. "ND0612's potential ability to provide steady, therapeutic levodopa levels could improve upon current symptomatic treatments for Parkinson's patients," said Todd Sherer, PhD, CEO of MJFF. "Finding such a drug remains a priority for the Foundation" "We thank The Michael J. Fox … Continue reading →

Posted in Parkinson's Treatment | Comments Off on NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinson's Disease

Jetstar refuses flight to disabled woman

Posted: Published on June 3rd, 2013

Australian budget airline, Jetstar, pulled a woman with cerebral palsy from a flight because it believed she could not understand instructions.AP Budget airline Jetstar pulled a woman with cerebral palsy from a flight because it believed she could not understand instructions. Ashley Papworth, 21, was travelling from Brisbane, Australia to Newcastle to visit her family, but was barred from the flight because cabin crew thought she was unable to understand what they were saying. Ms Papworth uses a wheelchair and hearing aid, but has travelled extensively without discrimination. Her grandfather, Michael Folbigg, said he was horrified by her treatment by the airline. "There were family members available to help Ashley on to the flight and also to help with her on arrival at Newcastle," Folbigg said. "(The airline) cited difficulties in communication as their reason for their refusal. Ashley is (diagnosed with) cerebral palsy, not an imbecile." A Jetstar spokesman said Papworth had travelled with family on previous occasions and the airline apologized for the inconvenience she suffered. "One of our key independent traveller requirements is that a passenger must be able to communicate that they have understood our crew's safety and emergency instructions," the spokesman said. "In this case, … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on Jetstar refuses flight to disabled woman

Page 5,205«..1020..5,2045,2055,2065,207..5,2105,220..»